Aptus Capital Advisors, LLC Biogen Inc. Transaction History

Aptus Capital Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Jul 22, 2020	SELL	$258.66 - $342.55 $2.28 Million - $3.02 Million	-8,826 Closed	0 $0
Q1 2020 May 07, 2020	BUY	$268.85 - $341.04 $266,968 - $338,652	993 Added 12.68%	8,826 $2.79 Million
Q4 2019 Feb 10, 2020	BUY	$220.06 - $304.07 $476,429 - $658,311	2,165 Added 38.2%	7,833 $2.32 Million
Q3 2019 Nov 12, 2019	SELL	$217.44 - $243.88 $275,931 - $309,483	-1,269 Reduced 18.29%	5,668 $1.32 Million
Q2 2019 Aug 13, 2019	BUY	$219.29 - $241.72 $443,404 - $488,757	2,022 Added 41.14%	6,937 $1.62 Million
Q1 2019 May 15, 2019	SELL	$216.71 - $338.96 $6,067 - $9,490	-28 Reduced 0.57%	4,915 $1.16 Million
Q4 2018 Feb 12, 2019	BUY	$278.5 - $352.75 $1.38 Million - $1.74 Million	4,943 New	4,943 $1.49 Million

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $22.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Aptus Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Aptus Capital Advisors, LLC with notifications on news.